Kyleena 19.5 MG systems
Ended Awarded Last action
- Contract number
- SPE2DR26FGER5
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $28,897
Award facts
- Contract value 100% obligated
- $28,896.72 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $28,896.72 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for Kyleena 19.5 mg contraceptive systems. The award, issued on January 7, 2026, with an ultimate completion date of January 29, 2026, carries no set-aside designation, indicating the contractor's ability to compete successfully in unrestricted federal procurement. This delivery order is issued under DMS Pharmaceutical Group's Indefinite Delivery Contract (IDC) with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion acquisition strategy that authorizes DLA to issue firm fixed-price delivery orders for comprehensive pharmaceutical products and medical consumables to support Department of Defense healthcare operations.
DMS Pharmaceutical Group has established itself as a critical supplier within the federal pharmaceutical supply chain, with demonstrated performance across multiple therapeutic categories and product lines including oncology treatments, biologics, vaccines, specialty pharmaceuticals, and routine medications. The company's prime vendor contract under PPV-G GEN V, awarded November 13, 2025, with a $499,999,999 ceiling value and completion date of December 31, 2036, positions it to serve military healthcare facilities worldwide. The single-award IDC structure enables the contractor to fulfill diverse and specialized pharmaceutical requirements for the Department of Defense medical system with a base period of 30 months followed by three 30-month option periods.
Quick answers
Who was awarded contract SPE2DR26FGER5?
SPE2DR26FGER5 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 7, 2026.
How much is contract SPE2DR26FGER5 worth?
The government has obligated $28,897 on SPE2DR26FGER5.
Is contract SPE2DR26FGER5 an order under another contract?
Yes. SPE2DR26FGER5 is a delivery order under SPE2DR25D9312, an indefinite delivery contract.
Was contract SPE2DR26FGER5 competed?
The extent of competition for SPE2DR26FGER5 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award